Savient Pharmaceuticals has reported that some production batches of Krystexxa, its recently-approved second-line treatment for gout, have failed to meet …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

